Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Phase III Olaparib Trial Misses OS Endpoint in Gastric Cancer

May 18th 2016

A phase III study exploring the combination of olaparib and paclitaxel missed its primary endpoint of improvement in overall survival compared with paclitaxel and placebo for patients with advanced gastric cancer.

Combined Vaccines Study Misses Primary Endpoint in Pancreatic Cancer

May 16th 2016

A regimen combining the vaccines CRS-207 and GVAX Pancreas failed to improve overall survival versus either CRS-207 alone or chemotherapy in patients with metastatic pancreatic cancer who had failed at least 2 prior therapies.

Pancreatic Cancer Vaccine Falls Short in Phase III Trial

May 10th 2016

The investigational pancreatic cancer vaccine algenpantucel-L failed to improve overall survival versus standard of care in the phase III IMPRESS trial.

Doxorubicin-Loaded Nanoparticle Formulation in Patients With HCC

May 6th 2016

Graham Dixon, PhD, chief scientific officer, Onxeo, discusses a mechanistic study of the relative cytotoxicity of doxorubicin-loaded nanoparticle formulation versus doxorubicin in hepatocellular carcinoma cell lines.

Regorafenib Improves Survival in Liver Cancer

May 4th 2016

Regorafenib (Stivarga) improved overall survival versus best supportive care in patients with unresectable hepatocellular carcinoma who progressed after receiving sorafenib (Nexavar).

Wendy Setiawan on Pancreatic Cancer Incidence Across Ethnic Populations

May 2nd 2016

Wendy Setiawan, PhD, assistant professor of Preventive Medicine, Department of Preventive Medicine, Keck School of Medicine of University of Southern California, discusses a study that examined differences in pancreatic cancer incidence across five racial/ethnic populations in a multiethnic cohort.

Dr. Van Morris on Nivolumab as a Potential Treatment for Patients With Anal Cancer

May 2nd 2016

Van K. Morris, MD, assistant professor of GI Oncology, The University of Texas MD Anderson Cancer Center, discusses a study examining nivolumab (Opdivo) as a potential treatment for patients with anal cancer.

Sequencing Agents in Metastatic Colorectal Cancer

April 28th 2016

Use of VEGF-Targeted Tyrosine Kinase Inhibitors

April 28th 2016

Patient Selection for Aflibercept in Advanced CRC

April 28th 2016

The Hunt for Predictive Biomarkers

April 28th 2016

Ramucirumab Data for Colorectal Cancer: Where Does it Fit In

April 28th 2016

What Is Clinically Meaningful?

April 28th 2016

Reviewing Ramucirumab Data for Lung Cancer

April 28th 2016

Trials of Ramucirumab in Gastric Cancer

April 28th 2016

Patient Selection for Antiangiogenic Therapy

April 28th 2016

Bevacizumab Use in Angiogenesis Clinical Practice

April 28th 2016

How Does Antiangiogenic Therapy Work?

April 28th 2016

Interplay Between Angiogenesis and Immunity

April 28th 2016

Angiogenesis in Tumor Growth and Metastasis

April 28th 2016